Long-acting siRNA therapies for hypertension offer a vaccine-like paradigm shift that removes the daily burden of adherence but may introduce behavioral risks such as pharmacological moral hazard.
Patients with hypertension
Long-acting siRNA therapies (e.g., zilebesiran)
Long-acting siRNA therapies for hypertension could solve daily adherence issues but require health systems to redesign care to maintain patient engagement in lifestyle modifications.
Abstract: Global hypertension control remains stagnant due to the fragility of daily medication adherence rather than a lack of effective drugs. Long-acting siRNA therapies offer a “vaccine-like” paradigm shift, transferring responsibility from the patient’s daily memory to the health system’s reliability. This approach introduces “pharmacological moral hazard,” where patients may neglect lifestyle modifications under a false sense of total security. Realizing the promise of democratized protection requires redesigning care pathways to ensure that infrequent dosing does not lead to clinical disengagement.
Building similarity graph...
Analyzing shared references across papers
Loading...
Lucas Maciel de Almeida Corrêa
Gabriel Rian Mazur
Clara Belo Gamon Santiago
Journal of Human Hypertension
Pontifícia Universidade Católica do Paraná
Faculdade de Medicina de São José do Rio Preto
Universidade Salvador
Building similarity graph...
Analyzing shared references across papers
Loading...
Corrêa et al. (Sat,) conducted a review in Hypertension. Long-acting siRNA therapies (e.g., zilebesiran) was evaluated. Long-acting siRNA therapies for hypertension offer a vaccine-like paradigm shift that removes the daily burden of adherence but may introduce behavioral risks such as pharmacological moral hazard.
www.synapsesocial.com/papers/69f04e08727298f751e7204a — DOI: https://doi.org/10.1038/s41371-026-01149-2